Literature DB >> 1508838

Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats.

R Pöyhiä1, E A Kalso.   

Abstract

Antinociception and central nervous system depression (CNSD) caused by intraperitoneal, intrathecal and subcutaneous administration of oxycodone or morphine were studied in a randomized and blind, saline controlled study in rats. Antinociception was assessed with the tail-flick and hot plate tests. CNSD was assessed by testing the corneal, placing and righting reflexes and with a 4-point catalepsy score. Intraperitoneally and subcutaneously administered oxycodone and morphine were given in doses of 2.5-10 and 5-20 mg kg-1 respectively. The intrathecal doses were 12.5 micrograms and 100 micrograms of oxycodone and 6.25 micrograms and 50 micrograms of morphine. In both nociceptive tests subcutaneously and intraperitoneally administered oxycodone was 2-4 times more potent than morphine, while intrathecal morphine was over 14 times more potent. CNSD was more profound with oxycodone than with morphine after intraperitoneal and subcutaneous administration, but was not observed after intratechal administration of either drug. Differences in opioid receptor affinities, liposolubilities and metabolism are discussed as possible explanations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1508838     DOI: 10.1111/j.1600-0773.1992.tb00441.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  20 in total

1.  Co-administration of oxycodone and morphine and analgesic synergy re-examined.

Authors:  Maree T Smith; Felix A de la Iglesia
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

2.  Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis.

Authors:  Hazem E Hassan; Alan L Myers; Insong J Lee; Hegang Chen; Andrew Coop; Natalie D Eddington
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

3.  Analgesic efficacy and pharmacokinetics of epidural oxycodone in pain management after gynaecological laparoscopy-A randomised, double blind, active control, double-dummy clinical comparison with intravenous administration.

Authors:  Panu Piirainen; Hannu Kokki; Brian Anderson; Jacqueline Hannam; Heidi Hautajärvi; Veli-Pekka Ranta; Merja Kokki
Journal:  Br J Clin Pharmacol       Date:  2019-06-20       Impact factor: 4.335

4.  Sex Differences in the Rat Hippocampal Opioid System After Oxycodone Conditioned Place Preference.

Authors:  James D Ryan; Yan Zhou; Natalina H Contoreggi; Farah K Bshesh; Jason D Gray; Joshua F Kogan; Konrad T Ben; Bruce S McEwen; Mary Jeanne Kreek; Teresa A Milner
Journal:  Neuroscience       Date:  2018-10-11       Impact factor: 3.590

5.  Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects.

Authors:  Zhi-Bing You; Guo-Hua Bi; Ewa Galaj; Vivek Kumar; Jianjing Cao; Alexandra Gadiano; Rana Rais; Barbara S Slusher; Eliot L Gardner; Zheng-Xiong Xi; Amy Hauck Newman
Journal:  Neuropsychopharmacology       Date:  2018-11-27       Impact factor: 7.853

6.  Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.

Authors:  Lillian Huang; Stephen R Edwards; Maree T Smith
Journal:  Pharm Res       Date:  2005-07-29       Impact factor: 4.200

Review 7.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

Review 8.  Oxycodone/Ibuprofen combination tablet: a review of its use in the management of acute pain.

Authors:  Vicki Oldfield; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  Pharmacodynamics and pharmacokinetics of the novel synthetic opioid, U-47700, in male rats.

Authors:  Michael T Truver; Christina R Smith; Nancy Garibay; Theresa A Kopajtic; Madeleine J Swortwood; Michael H Baumann
Journal:  Neuropharmacology       Date:  2020-06-10       Impact factor: 5.250

Review 10.  Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.

Authors:  Cherkaouia Kibaly; Jacob A Alderete; Steven H Liu; Hazem S Nasef; Ping-Yee Law; Christopher J Evans; Catherine M Cahill
Journal:  Cell Mol Neurobiol       Date:  2020-11-27       Impact factor: 4.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.